STANDARD BIOTOOLS INC (LAB)

US34385P1084 - Common Stock

2.01  -0.05 (-2.43%)

After market: 2.01 0 (0%)

Fundamental Rating

3

Overall LAB gets a fundamental rating of 3 out of 10. We evaluated LAB against 57 industry peers in the Life Sciences Tools & Services industry. While LAB seems to be doing ok healthwise, there are quite some concerns on its profitability. LAB is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LAB has reported negative net income.
In the past year LAB has reported a negative cash flow from operations.
LAB had negative earnings in each of the past 5 years.
In the past 5 years LAB always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -25.03%, LAB is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
LAB's Return On Equity of -34.86% is in line compared to the rest of the industry. LAB outperforms 40.35% of its industry peers.
Industry RankSector Rank
ROA -25.03%
ROE -34.86%
ROIC N/A
ROA(3y)-31.11%
ROA(5y)-26.82%
ROE(3y)-63.68%
ROE(5y)-54.27%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 48.57%, LAB perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
LAB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-2.74%

More info and screens

4

2. Health

2.1 Basic Checks

LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LAB has more shares outstanding
LAB has more shares outstanding than it did 5 years ago.
LAB has a worse debt/assets ratio than last year.

2.2 Solvency

LAB has an Altman-Z score of 0.20. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.20, LAB is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
LAB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LAB (0.00) is better than 78.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC10.69%

2.3 Liquidity

LAB has a Current Ratio of 3.76. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB has a better Current ratio (3.76) than 63.16% of its industry peers.
LAB has a Quick Ratio of 3.41. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB has a Quick ratio of 3.41. This is in the better half of the industry: LAB outperforms 64.91% of its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.41

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.13% over the past year.
LAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.22%.
LAB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.21% yearly.
EPS 1Y (TTM)10.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
Revenue 1Y (TTM)48.22%
Revenue growth 3Y-8.34%
Revenue growth 5Y-1.21%
Sales Q2Q%77.27%

3.2 Future

LAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.57% yearly.
Based on estimates for the next years, LAB will show a very strong growth in Revenue. The Revenue will grow by 25.15% on average per year.
EPS Next Y38.21%
EPS Next 2Y31.86%
EPS Next 3Y23.71%
EPS Next 5Y18.57%
Revenue Next Year66.21%
Revenue Next 2Y34.72%
Revenue Next 3Y29.6%
Revenue Next 5Y25.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LAB's earnings are expected to grow with 23.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3Y23.71%

More info and screens

0

5. Dividend

5.1 Amount

LAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STANDARD BIOTOOLS INC

NASDAQ:LAB (1/14/2025, 8:00:02 PM)

After market: 2.01 0 (0%)

2.01

-0.05 (-2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)N/A N/A
Inst Owners72.07%
Inst Owner ChangeN/A
Ins Owners1.76%
Ins Owner Change-0.27%
Market Cap748.24M
Analysts82.86
Price Target3.14 (56.22%)
Short Float %3.7%
Short Ratio6.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.39%
Min EPS beat(2)-39.78%
Max EPS beat(2)22.99%
EPS beat(4)1
Avg EPS beat(4)-60.77%
Min EPS beat(4)-135.88%
Max EPS beat(4)22.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.53%
Min Revenue beat(2)-23.66%
Max Revenue beat(2)8.6%
Revenue beat(4)2
Avg Revenue beat(4)-1.24%
Min Revenue beat(4)-23.66%
Max Revenue beat(4)12.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.8
P/FCF N/A
P/OCF N/A
P/B 1.53
P/tB 2.08
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.42
BVpS1.31
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.03%
ROE -34.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.57%
FCFM N/A
ROA(3y)-31.11%
ROA(5y)-26.82%
ROE(3y)-63.68%
ROE(5y)-54.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-2.74%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.05%
Cap/Sales 3.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.41
Altman-Z 0.2
F-Score5
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)43.1%
Cap/Depr(5y)45.04%
Cap/Sales(3y)5.58%
Cap/Sales(5y)5.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
EPS Next Y38.21%
EPS Next 2Y31.86%
EPS Next 3Y23.71%
EPS Next 5Y18.57%
Revenue 1Y (TTM)48.22%
Revenue growth 3Y-8.34%
Revenue growth 5Y-1.21%
Sales Q2Q%77.27%
Revenue Next Year66.21%
Revenue Next 2Y34.72%
Revenue Next 3Y29.6%
Revenue Next 5Y25.15%
EBIT growth 1Y-73.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.19%
EBIT Next 3Y25.42%
EBIT Next 5Y30.85%
FCF growth 1Y-83.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.84%
OCF growth 3YN/A
OCF growth 5YN/A